# A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

> **NCT02492321** · PHASE3 · COMPLETED · sponsor: **Eleven Biotherapeutics** · enrollment: 250 (actual)

## Conditions studied

- Allergic Conjunctivitis (AC)

## Interventions

- **DRUG:** EBI-005
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT02492321
- **Lead sponsor:** Eleven Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2016-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02492321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02492321, "A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02492321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*